Graves' disease development during sizofiran treatment

Internal Medicine

Volumn 41, Issue 11, 2002, Pages 977-978

  Morita, Shigeki ^a   Ueda, Yasuo ^a  

^a JAPANESE RED CROSS NAGASAKI GENBAKU HOSPITAL   (Japan)

Author keywords

Autoimmune thyroid disease; Endometrial carcinoma

Indexed keywords

ESTRADIOL; NEDAPLATIN; PROPYLTHIOURACIL; SCHIZOPHYLLAN; THYROTROPIN RECEPTOR ANTIBODY; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; EUTHYROIDISM; FEMALE; GOITER; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; IMMUNOREACTIVITY; IMMUNOTHERAPY; THYROID SCINTISCANNING; THYROTOXICOSIS; CHEMICALLY INDUCED DISORDER;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; GRAVES DISEASE; HUMANS; SIZOFIRAN;

EID: 0036859912     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.41.977     Document Type: Article

References (17)

1. Okamura K, Suzuki M, Chirara T, et al. Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer. A randomized controlled study. Cancer 58: 865-872, 1986.
2. Okamura K, Suzuki M, Chihara T, et al. Clinical evaluation of sizofiran combined with irradiation in patients with cervical cancer. A randomized controlled study; a five-year survival rate. Biotherapy 1: 103-107, 1989.
3. Noda K, Takeuchi S, Yajima A, et al. Clinical effect of sizofiran combined with irradiation in cervical cancer patients: A randomized controlled study. Jpn J Clin Oncol 22: 17-25, 1992.
4. Furue H. Biological characteristics and clinical effect of sizofiran. Drugs of Today 23: 335-346, 1987.
5. Amino N, Mori H, Iwatani Y, et al. High prevalence of transient postpartum thyrotoxicosis and hypothyroidism. N Engl J Med 306: 849-852, 1982.
6. Hidaka Y, Amino N, Iwatani Y, Itoh E, Matsunaga M, Tamaki H. Recurrence of thyrotoxicosis after attack of allergic rhinitis in patients with Graves' disease. J Clin Endocrinol Metab 77: 1667-1670, 1993.
7. Rajatanavin R, Safran M, Stoller WA, Mordes JP, Braverman LE. Five patients with iodine-induced hyperthyroidism. Am J Med 77: 378-384, 1984.
8. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: Results of a prospective study. J Clin Endocrinol Metab 81: 2930-2933, 1996.
9. Wada M, Hiraizumi W, Fujimoto M, et al. Occurrence of Graves' disease during retreatment with interferon-α2a for chronic hepatitis C. Intern Med 34: 1097-1100, 1995.
10. Rotondi M, Mazziotti G, Biondi B, et al. Long-term treatment with interferon-β therapy for multiple sclerosis and occurrence of Graves' disease. J Endocrinol Invest 23: 321-324, 2000.
11. Morita S, Ueda Y, Yokoyama N. Painless thyroiditis induced by the cessation of betamethasone. Intern Med 40: 744-746, 2001.
12. Suzuki M, Arika T, Amemiya K, Fujiwara, M. Cooperative role of T lymphocytes and macrophages in anti-tumor activity of mice pretreated with schizophyllan (SPG). Jpn J Exp Med 52: 59-65, 1982.
13. Sugawara I, Lee KC, Wong M. Schizophyllan (SPG)-treated macrophages and anti-tumor activities against syngeneic and allogeneic tumor cells. Cancer Immunol Immunother 16: 137-144, 1984.
14. Tsuchiya Y, Igarashi M, Inoue M, Kumagai K. Cytokine-related immunomodulating activities of an anti-tumor glucan, sizofiran (SPG). J Pharmacobiodyn 12: 616-625, 1989.
15. Yoshioka T, Gamoh M, Shineha R, et al. A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers. Intern Med 38: 844-848, 1999.
16. Adachi S, Ogasawara T, Wakimoto E, et al. Phase I/II study of intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical carcinoma. Cancer 91: 74-79, 2001.
17. Amino N, Tada H, Hidaka Y, Izumi Y. Postpartum autoimmune thyroid syndrome. Endocrine J 147: 645-655, 2000.